Loading…
Experiments in social responsibility
Pursuing drugs for neglected diseases is not a traditional part of the pharmaceutical company portfolio. But Paul Herrling of Novartis finds that it brings welcome changes both within and outside the industry. Adopt a disease The Novartis research facility in Singapore, focusing on dengue fever and...
Saved in:
| Published in: | Nature (London) 2006-01, Vol.439 (7074), p.267-268 |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c752t-f16f4effa0d0daad1499567c2ee4bac86ebe79a266f5cdcac376608ce5cf3e773 |
|---|---|
| cites | |
| container_end_page | 268 |
| container_issue | 7074 |
| container_start_page | 267 |
| container_title | Nature (London) |
| container_volume | 439 |
| creator | Herrling, Paul |
| description | Pursuing drugs for neglected diseases is not a traditional part of the pharmaceutical company portfolio. But Paul Herrling of Novartis finds that it brings welcome changes both within and outside the industry.
Adopt a disease
The Novartis research facility in Singapore, focusing on dengue fever and tuberculosis, reflects a new approach from pharmaceuticals companies keen to show their soft side. Market forces have failed to generate the research needed for the development of drugs to treat rare or ‘orphan’ diseases in developing countries. In a Commentary, Novartis's head of corporate research argues that a new culture is emerging throughout the industry that recognizes a need to temper the commercial imperative with a social approach to developing drugs that will not generate high profits. |
| doi_str_mv | 10.1038/439267a |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_743577764</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A185466001</galeid><sourcerecordid>A185466001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c752t-f16f4effa0d0daad1499567c2ee4bac86ebe79a266f5cdcac376608ce5cf3e773</originalsourceid><addsrcrecordid>eNqN0-9L3DAYB_AwNuapY__BOMbYFKlL0vxoXx6Hc4IoqGMvQy59ckR6aU1a0P_eyBXsib_Ii0L6yTd54HkQ-krwIcF58ZvlJRVSf0ATwqTImCjkRzTBmBYZLnKxhbZjvMYYcyLZZ7RFBKOEMzlBP45uWwhuBb6LU-ensTFO19MAsW18dAtXu-5uF32yuo7wZfjuoH9_jq7mf7PT8-OT-ew0M5LTLrNEWAbWalzhSuuKsLLkQhoKwBbaFAIWIEtNhbDcVEabXAqBCwPc2BykzHfQr3VuG5qbHmKnVi4aqGvtoemjkiznUkrBkvz5usSiLKUkCX5_Aq-bPvhUhaKYcYpz_ICyNVrqGpTztumCNkvwEHTdeLAubc8ETdenisp3elJwlurDo0dseNO6GzUOfRGNkw6fQWlVsHLm2ae-68D4hv2NA8l0cNstdR-jOrm82Ax_y45zD162s6v_87PN5Lf1OHvoGxOaGANY1aaW1uFOEawe5kMN85Hkt6Ed-sUKqkc3DEQCe2sQ0y-_hPDYL0-z7gEChg47</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>204520301</pqid></control><display><type>article</type><title>Experiments in social responsibility</title><source>Nature</source><creator>Herrling, Paul</creator><creatorcontrib>Herrling, Paul</creatorcontrib><description>Pursuing drugs for neglected diseases is not a traditional part of the pharmaceutical company portfolio. But Paul Herrling of Novartis finds that it brings welcome changes both within and outside the industry.
Adopt a disease
The Novartis research facility in Singapore, focusing on dengue fever and tuberculosis, reflects a new approach from pharmaceuticals companies keen to show their soft side. Market forces have failed to generate the research needed for the development of drugs to treat rare or ‘orphan’ diseases in developing countries. In a Commentary, Novartis's head of corporate research argues that a new culture is emerging throughout the industry that recognizes a need to temper the commercial imperative with a social approach to developing drugs that will not generate high profits.</description><identifier>ISSN: 0028-0836</identifier><identifier>EISSN: 1476-4687</identifier><identifier>DOI: 10.1038/439267a</identifier><identifier>PMID: 16421547</identifier><identifier>CODEN: NATUAS</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Bioethics ; Charities - economics ; Charities - trends ; commentary ; Corporate social responsibility ; Dengue - drug therapy ; Dengue fever ; Developing Countries ; Disease ; Drug Industry - economics ; Drug Industry - trends ; Drug therapy ; Drugs ; Global Health ; Humanities and Social Sciences ; Humans ; LDCs ; multidisciplinary ; NGOs ; Nongovernmental organizations ; Orphan drugs ; Patents as Topic ; Pharmaceutical industry ; Planning ; Product development ; Science ; Science (multidisciplinary) ; Social responsibility ; Tuberculosis ; Tuberculosis - drug therapy</subject><ispartof>Nature (London), 2006-01, Vol.439 (7074), p.267-268</ispartof><rights>Springer Nature Limited 2006</rights><rights>COPYRIGHT 2006 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jan 19, 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c752t-f16f4effa0d0daad1499567c2ee4bac86ebe79a266f5cdcac376608ce5cf3e773</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16421547$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Herrling, Paul</creatorcontrib><title>Experiments in social responsibility</title><title>Nature (London)</title><addtitle>Nature</addtitle><addtitle>Nature</addtitle><description>Pursuing drugs for neglected diseases is not a traditional part of the pharmaceutical company portfolio. But Paul Herrling of Novartis finds that it brings welcome changes both within and outside the industry.
Adopt a disease
The Novartis research facility in Singapore, focusing on dengue fever and tuberculosis, reflects a new approach from pharmaceuticals companies keen to show their soft side. Market forces have failed to generate the research needed for the development of drugs to treat rare or ‘orphan’ diseases in developing countries. In a Commentary, Novartis's head of corporate research argues that a new culture is emerging throughout the industry that recognizes a need to temper the commercial imperative with a social approach to developing drugs that will not generate high profits.</description><subject>Bioethics</subject><subject>Charities - economics</subject><subject>Charities - trends</subject><subject>commentary</subject><subject>Corporate social responsibility</subject><subject>Dengue - drug therapy</subject><subject>Dengue fever</subject><subject>Developing Countries</subject><subject>Disease</subject><subject>Drug Industry - economics</subject><subject>Drug Industry - trends</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Global Health</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>LDCs</subject><subject>multidisciplinary</subject><subject>NGOs</subject><subject>Nongovernmental organizations</subject><subject>Orphan drugs</subject><subject>Patents as Topic</subject><subject>Pharmaceutical industry</subject><subject>Planning</subject><subject>Product development</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Social responsibility</subject><subject>Tuberculosis</subject><subject>Tuberculosis - drug therapy</subject><issn>0028-0836</issn><issn>1476-4687</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqN0-9L3DAYB_AwNuapY__BOMbYFKlL0vxoXx6Hc4IoqGMvQy59ckR6aU1a0P_eyBXsib_Ii0L6yTd54HkQ-krwIcF58ZvlJRVSf0ATwqTImCjkRzTBmBYZLnKxhbZjvMYYcyLZZ7RFBKOEMzlBP45uWwhuBb6LU-ensTFO19MAsW18dAtXu-5uF32yuo7wZfjuoH9_jq7mf7PT8-OT-ew0M5LTLrNEWAbWalzhSuuKsLLkQhoKwBbaFAIWIEtNhbDcVEabXAqBCwPc2BykzHfQr3VuG5qbHmKnVi4aqGvtoemjkiznUkrBkvz5usSiLKUkCX5_Aq-bPvhUhaKYcYpz_ICyNVrqGpTztumCNkvwEHTdeLAubc8ETdenisp3elJwlurDo0dseNO6GzUOfRGNkw6fQWlVsHLm2ae-68D4hv2NA8l0cNstdR-jOrm82Ax_y45zD162s6v_87PN5Lf1OHvoGxOaGANY1aaW1uFOEawe5kMN85Hkt6Ed-sUKqkc3DEQCe2sQ0y-_hPDYL0-z7gEChg47</recordid><startdate>20060119</startdate><enddate>20060119</enddate><creator>Herrling, Paul</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ATWCN</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7ST</scope><scope>7T5</scope><scope>7TG</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>BKSAR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PCBAR</scope><scope>PDBOC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>Q9U</scope><scope>R05</scope><scope>RC3</scope><scope>S0X</scope><scope>SOI</scope><scope>7X8</scope><scope>7SC</scope><scope>7SP</scope><scope>7SR</scope><scope>7TB</scope><scope>7U5</scope><scope>8BQ</scope><scope>F28</scope><scope>JG9</scope><scope>JQ2</scope><scope>KR7</scope><scope>L7M</scope><scope>L~C</scope><scope>L~D</scope></search><sort><creationdate>20060119</creationdate><title>Experiments in social responsibility</title><author>Herrling, Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c752t-f16f4effa0d0daad1499567c2ee4bac86ebe79a266f5cdcac376608ce5cf3e773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Bioethics</topic><topic>Charities - economics</topic><topic>Charities - trends</topic><topic>commentary</topic><topic>Corporate social responsibility</topic><topic>Dengue - drug therapy</topic><topic>Dengue fever</topic><topic>Developing Countries</topic><topic>Disease</topic><topic>Drug Industry - economics</topic><topic>Drug Industry - trends</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Global Health</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>LDCs</topic><topic>multidisciplinary</topic><topic>NGOs</topic><topic>Nongovernmental organizations</topic><topic>Orphan drugs</topic><topic>Patents as Topic</topic><topic>Pharmaceutical industry</topic><topic>Planning</topic><topic>Product development</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Social responsibility</topic><topic>Tuberculosis</topic><topic>Tuberculosis - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Herrling, Paul</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Middle School</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Environment Abstracts</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Earth, Atmospheric & Aquatic Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>Biological Sciences</collection><collection>Agriculture Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Earth, Atmospheric & Aquatic Science Database</collection><collection>Materials Science Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><collection>University of Michigan</collection><collection>Genetics Abstracts</collection><collection>SIRS Editorial</collection><collection>Environment Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Computer and Information Systems Abstracts</collection><collection>Electronics & Communications Abstracts</collection><collection>Engineered Materials Abstracts</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>METADEX</collection><collection>ANTE: Abstracts in New Technology & Engineering</collection><collection>Materials Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>Civil Engineering Abstracts</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Computer and Information Systems Abstracts Academic</collection><collection>Computer and Information Systems Abstracts Professional</collection><jtitle>Nature (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Herrling, Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Experiments in social responsibility</atitle><jtitle>Nature (London)</jtitle><stitle>Nature</stitle><addtitle>Nature</addtitle><date>2006-01-19</date><risdate>2006</risdate><volume>439</volume><issue>7074</issue><spage>267</spage><epage>268</epage><pages>267-268</pages><issn>0028-0836</issn><eissn>1476-4687</eissn><coden>NATUAS</coden><abstract>Pursuing drugs for neglected diseases is not a traditional part of the pharmaceutical company portfolio. But Paul Herrling of Novartis finds that it brings welcome changes both within and outside the industry.
Adopt a disease
The Novartis research facility in Singapore, focusing on dengue fever and tuberculosis, reflects a new approach from pharmaceuticals companies keen to show their soft side. Market forces have failed to generate the research needed for the development of drugs to treat rare or ‘orphan’ diseases in developing countries. In a Commentary, Novartis's head of corporate research argues that a new culture is emerging throughout the industry that recognizes a need to temper the commercial imperative with a social approach to developing drugs that will not generate high profits.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>16421547</pmid><doi>10.1038/439267a</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-0836 |
| ispartof | Nature (London), 2006-01, Vol.439 (7074), p.267-268 |
| issn | 0028-0836 1476-4687 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_743577764 |
| source | Nature |
| subjects | Bioethics Charities - economics Charities - trends commentary Corporate social responsibility Dengue - drug therapy Dengue fever Developing Countries Disease Drug Industry - economics Drug Industry - trends Drug therapy Drugs Global Health Humanities and Social Sciences Humans LDCs multidisciplinary NGOs Nongovernmental organizations Orphan drugs Patents as Topic Pharmaceutical industry Planning Product development Science Science (multidisciplinary) Social responsibility Tuberculosis Tuberculosis - drug therapy |
| title | Experiments in social responsibility |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T17%3A22%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Experiments%20in%20social%20responsibility&rft.jtitle=Nature%20(London)&rft.au=Herrling,%20Paul&rft.date=2006-01-19&rft.volume=439&rft.issue=7074&rft.spage=267&rft.epage=268&rft.pages=267-268&rft.issn=0028-0836&rft.eissn=1476-4687&rft.coden=NATUAS&rft_id=info:doi/10.1038/439267a&rft_dat=%3Cgale_proqu%3EA185466001%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c752t-f16f4effa0d0daad1499567c2ee4bac86ebe79a266f5cdcac376608ce5cf3e773%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=204520301&rft_id=info:pmid/16421547&rft_galeid=A185466001&rfr_iscdi=true |